DARZALEX FASPRO®
(daratumumab and hyaluronidase-fihj)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information
DARZALEX FASPRO - Density and Fill Volume
Last Updated: 05/23/2024
SUMMARY
- Janssen cannot recommend any practices, procedures, or storage conditions that deviate from product labeling and are not approved by the regulatory agencies.
- DARZALEX FASPRO solution for subcutaneous (SC) injection is for single use only.1
- Each single-use vial contains 15 mL nominal fill volume plus overfill to allow for delivery of 1800 mg daratumumab (120 mg/mL).1,
2 - The content in the co-formulated DARZALEX FASPRO product solution is presented in the table: Density and Fill Volume of Co-Formulated DARZALEX FASPRO Product Solution.2,3
Literature Search
A literature search of MEDLINE®
References
| 1 | Data on File. Daratumumab SC Company Core Data Sheet (CCDS). Janssen Research & Development, LLC. EDMS-ERI-184804517; 2024. |
| 2 | |
| 3 |